Dimensional Fund Advisors LP increased its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 12.1% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,866,887 shares of the specialty pharmaceutical company's stock after purchasing an additional 309,966 shares during the quarter. Dimensional Fund Advisors LP owned 5.22% of Supernus Pharmaceuticals worth $76,690,000 as of its most recent filing with the SEC.
A number of other large investors have also bought and sold shares of SUPN. Commonwealth Equity Services LLC grew its stake in shares of Supernus Pharmaceuticals by 3.6% during the 2nd quarter. Commonwealth Equity Services LLC now owns 10,195 shares of the specialty pharmaceutical company's stock worth $273,000 after acquiring an additional 350 shares in the last quarter. Covestor Ltd raised its stake in Supernus Pharmaceuticals by 15.3% during the first quarter. Covestor Ltd now owns 2,702 shares of the specialty pharmaceutical company's stock worth $92,000 after acquiring an additional 358 shares in the last quarter. Louisiana State Employees Retirement System raised its stake in Supernus Pharmaceuticals by 2.2% during the second quarter. Louisiana State Employees Retirement System now owns 27,700 shares of the specialty pharmaceutical company's stock worth $741,000 after acquiring an additional 600 shares in the last quarter. Texas Permanent School Fund Corp raised its stake in Supernus Pharmaceuticals by 1.3% during the first quarter. Texas Permanent School Fund Corp now owns 47,814 shares of the specialty pharmaceutical company's stock worth $1,631,000 after acquiring an additional 619 shares in the last quarter. Finally, Fidelis Capital Partners LLC acquired a new position in shares of Supernus Pharmaceuticals in the first quarter valued at approximately $33,000.
Supernus Pharmaceuticals Stock Performance
Shares of NASDAQ SUPN traded up $0.39 during mid-day trading on Friday, hitting $31.16. 43,271 shares of the stock traded hands, compared to its average volume of 465,480. Supernus Pharmaceuticals, Inc. has a 52 week low of $21.99 and a 52 week high of $35.44. The company has a market cap of $1.72 billion, a price-to-earnings ratio of -106.10 and a beta of 0.88. The stock has a fifty day moving average price of $32.26 and a 200-day moving average price of $30.45.
Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported $0.36 EPS for the quarter, missing analysts' consensus estimates of $0.39 by ($0.03). Supernus Pharmaceuticals had a net margin of 0.83% and a return on equity of 0.56%. The firm had revenue of $168.30 million for the quarter, compared to analysts' expectations of $148.83 million. During the same quarter last year, the company posted ($0.02) EPS. The firm's revenue was up 24.1% compared to the same quarter last year. As a group, sell-side analysts predict that Supernus Pharmaceuticals, Inc. will post 1.53 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of analysts have weighed in on the stock. StockNews.com raised shares of Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Wednesday, August 7th. Piper Sandler lowered Supernus Pharmaceuticals from an "overweight" rating to a "neutral" rating and decreased their price objective for the stock from $41.00 to $36.00 in a report on Wednesday, September 11th.
Check Out Our Latest Stock Analysis on SUPN
Supernus Pharmaceuticals Profile
(
Free Report)
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.
Read More
Before you consider Supernus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Supernus Pharmaceuticals wasn't on the list.
While Supernus Pharmaceuticals currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
